Technical Analysis for MCRB - Seres Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 4.13 -4.18% -0.18
MCRB closed down 4.18 percent on Friday, May 17, 2019, on 31 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
1 Watcher
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical MCRB trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Low Weakness -4.18%
Wide Bands Range Expansion -4.18%
Oversold Stochastic Weakness -4.18%
New 52 Week Closing Low Bearish -2.36%
Wide Bands Range Expansion -2.36%
Down 3 Days in a Row Weakness -2.36%
Down 4 Days in a Row Weakness -2.36%

Older signals for MCRB ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators
Basic chart:
Profile
Seres Therapeutics, Inc., a microbiome therapeutics platform company, focuses on the development of biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which has completed open label Phase Ib/2 clinical study for the prevention of further recurrences of Clostridium difficile infection (CDI). The company's product candidates in pre-clinical development comprise SER-262, an Ecobiotic microbiome therapeutic designed to be used following antibiotic treatment of primary CDI to prevent the initial recurrence of CDI; SER-287 to treat inflammatory bowel disease, including ulcerative colitis; and SER-155 to treat enteric pathogens, such as antibiotic-resistant bacteria. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Medicine Medical Specialties Autoimmune Diseases Inflammatory Bowel Disease Ulcerative Colitis Diarrhea Antimicrobial Resistance Digestive Diseases Clostridioides Difficile Clostridium Difficile Infection
Is MCRB a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
May 14 The Daily Biotech Pulse: Further Delay in Roche's Spark Acquisition, FDA Nod For Regeneron, Solid Biosciences Sinks On Earnings
May 6 Seres Therapeutics (MCRB) CEO Eric Shaff on Q1 2019 Results - Earnings Call Transcript
May 3 78 Biggest Movers From Yesterday
May 2 Edited Transcript of MCRB earnings conference call or presentation 2-May-19 12:30pm GMT
May 2 Seres Therapeutics (MCRB) Reports Q1 Loss, Lags Revenue Estimates
May 2 Seres Therapeutics: 1Q Earnings Snapshot
May 2 Seres Therapeutics misses by $0.13, misses on revenue
May 2 Seres Therapeutics Reports First Quarter Financial Results and Provides Clinical Pipeline Progress Update
May 2 Seres Therapeutics, Inc. to Host Earnings Call
Apr 29 Seres Therapeutics to Host First Quarter 2019 Financial Results and Operational Progress Conference Call and Webcast on May 2, 2019
See more MCRB news...
Indicators
Indicator Value
52 Week High 9.75
52 Week Low 4.04
Average Volume 462,128
200-Day Moving Average 6.7571
50-Day Moving Average 6.1678
20-Day Moving Average 5.5155
10-Day Moving Average 4.527
Average True Range 0.3749
ADX 35.16
+DI 10.5412
-DI 33.7473
Chandelier Exit (Long, 3 ATRs ) 6.2653
Chandelier Exit (Short, 3 ATRs ) 5.1647
Upper Bollinger Band 7.7868
Lower Bollinger Band 3.2442
Percent B (%b) 0.19
BandWidth 82.36062
MACD Line -0.6427
MACD Signal Line -0.5061
MACD Histogram -0.1366
Fundamentals Value
Market Cap 167.31 Million
Num Shares 40.5 Million
EPS -2.42
Price-to-Earnings (P/E) Ratio -1.71
Price-to-Sales 17.96
Price-to-Book 4.50
PEG Ratio 0.03
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.54
Resistance 3 (R3) 4.56 4.44 4.47
Resistance 2 (R2) 4.44 4.34 4.43 4.44
Resistance 1 (R1) 4.29 4.28 4.23 4.27 4.42
Pivot Point 4.17 4.17 4.15 4.16 4.17
Support 1 (S1) 4.02 4.07 3.96 4.00 3.84
Support 2 (S2) 3.90 4.01 3.89 3.82
Support 3 (S3) 3.75 3.90 3.79
Support 4 (S4) 3.73